AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 182 min read$BCDA

Altman Peter purchased $5K of BCDA

Altman Peter (President and CEO) purchased 5,400 shares of BioCardia, Inc. (BCDA) at $0.93 on 2026-08-17.

Original reporting
SEC EDGAR · Altman Peter
Published Aug 18, 2026, 4:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 4:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BCDA
Neutral
low confidence
Mentioned
$BCDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDANeutralLow
01

Why it matters

The newest fact is the CEO’s open-market purchase details (5,400 shares at $0.93) and the absence of a pre-arranged 10b5-1 plan, which can slightly increase perceived conviction but does not change fundamentals by itself.

02

Market read

Traders may note the insider buy as a minor sentiment input, but there is no guidance, trial, deal, or regulatory catalyst in the text.

03

What to watch

The article provides no context on prior insider activity, total insider ownership changes over time, or whether the purchase size is meaningful versus typical CEO buying patterns.

Relevance 4/10Novelty 3/10Timing: today’s SEC Form 4 filing (filed 2026-08-18)

Background

The article is an SEC Form 4 insider transaction disclosure for BioCardia, Inc. (BCDA).

Company-level read

Ticker impact

$BCDANeutralLow confidence
Context

BioCardia CEO Altman Peter filed a Form 4 open-market purchase of 5,400 shares at $0.93 on 2026-08-17.

Expected impact

Likely limited near-term price impact; any effect is sentiment-driven and typically fades unless followed by larger actions or company catalysts.

Evidence & confidence

The filing is a routine insider open-market purchase with no 10b5-1 plan and no accompanying operational or financial disclosure in the text.

Market effects

Sector

No sector-level implications from a single small insider purchase.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider open-market buys are often discretionary and can be driven by liquidity needs or diversification rather than a strong forward-looking view.

Key entities

  • issuer
    BioCardia, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Altman Peter

    President and CEO who reported the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BCDA insider trading history →

Related articles

OCT 19
$BCDAMedAI 8/10

BioCardia Advances Helix Catheter Toward FDA Marketing Clearance

BioCardia (BCDA) submitted a revised De Novo pre-submission package to the FDA for its Helix catheter, following feedback. The FDA accepted the submission and expects review, feedback, and a meeting in Q4 2026. The catheter is designed for delivering therapeutic agents to heart muscle and has clinical safety data from 15 trials. FDA clearance could expand partnership opportunities for BCDA.

rttnews.com2 min
OCT 19
$BCDAHighAI 8/10

BioCardia: FDA Accepts De Novo Pre-Submission for Helix Catheter; Substantive Review, Meeting Expected This Quarter

BioCardia's FDA pre-submission for Helix catheter was accepted, with substantive review and a meeting expected this quarter. The FDA raised no concerns about safety or performance. The company has clinical data from 15 trials supporting potential clearance, which could expand partnerships. According to the company, marketing clearance could enhance opportunities with cardiac biologics developers.

tradingview.com1 min
OCT 19
$BCDAMedAI 8/10

FDA accepts BioCardia pre-submission for Helix catheter

BioCardia Inc. (BCDA) announced the FDA accepted its pre-submission for the Helix catheter, a device for heart agent delivery. The FDA indicated two pathways for clearance and raised no safety concerns. BioCardia expects substantive review and feedback this quarter. The Helix catheter is supported by clinical data from 15 trials with nearly 500 patients.

investing.com2 min
OCT 19
$BCDAHighAI 8/10

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for HelixTM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix TM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter October 19, 2026, Sunnyvale, Calif. BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular an

SEC EDGAR 8-K2 min